Decitabine + Cedazuridine Suppliers & Bulk Manufacturers
Available Forms: Tablets
Available Strengths: 35 mg + 100mg
Reference Brands: Inqovi (USA/EU)
Category: Oncology Cancer Care
Decitabine/cedazuridine is an oral fixed-dose combination used for the treatment of myelodysplastic syndromes and chronic myelomonocytic leukemia. Cedazuridine improves oral absorption of decitabine by inhibiting its breakdown, allowing patients to receive effective decitabine therapy without injections. Decitabine + Cedazuridine is available in Tablets and strengths such as 35 mg + 100mg. Sourced from GMP-certified and ISO-compliant manufacturers, this API meets global pharmacopeia standards (USP/EP/JP as applicable). Ideal for pharmaceutical formulation and commercial manufacturing, Decitabine + Cedazuridine is supplied in bulk quantities with complete regulatory support including DMF, COA, and MSDS.
| Technical Specifications & Supply Details | |
|---|---|
| Lead Time | 7 to 60 days (depending on batch size & schedule) |
| MOQ | As per manufacturer’s batch size |
| COA | Available with every batch |
| Regulatory Dossier / DMF | Available upon request |
| Export Documentation | FSC, COA, Manufacturing License, Product Permission |
| Standards | IP, BP, USP |
| Certifications | WHO-GMP, EU-GMP, USFDA (as applicable) |
Decitabine + Cedazuridine can be exported to over 30 countries across Asia, Africa, Europe, and Latin America. Flexible packaging, competitive pricing, and a verified supplier network make Pharmatradz a trusted sourcing partner for pharmaceutical companies and contract manufacturers worldwide.
The Trade Mark owner has been correctly identified under the heading Manufacturer / TM Owner as required by the Act.
Frequently Asked Questions
Decitabine + Cedazuridine is used for treating myelodysplastic syndromes and chronic myelomonocytic leukemia. Decitabine provides hypomethylating activity, while cedazuridine increases its oral absorption by inhibiting cytidine deaminase, allowing decitabine to achieve therapeutic systemic levels through an oral dosage.
Decitabine + Cedazuridine is made from two active components: decitabine, a DNA hypomethylating agent, and cedazuridine, an inhibitor of cytidine deaminase. Together, they enable effective oral administration of decitabine.
The trade name is Inqovi.
Inqovi is manufactured by Taiho Oncology and Astex Pharmaceuticals.
The generic name is decitabine and cedazuridine.
The brand name is Inqovi.
Decitabine + Cedazuridine is manufactured in the United States and Canada under Taiho and Astex production facilities for regulated markets.
Related Products
Gemtuzumab Ozogamicin
Strength:
4.5 mg
Form: Injection
Reference Brands: Mylotarg (USA)
View Details
Tafasitamab‑Cxix
Strength:
200 mg
Form: Injection
Reference Brands: Monjuvi (USA), Minjuvi (EU)
View Details
Dordaviprone Hydrochloride
Strength:
125 mg
Form: Capsules
Reference Brands: Modeyso (USA)
View Details
Quick Response Guaranteed | Verified Suppliers
